(Credit-Canva)
Sometimes the food you eat or the behavior you exhibit can be a sign of a deficiency and condition you may have. It is similar to when your stomach growls, which signifies that you are hungry. Other signs you may not know about are feeling fatigued when you do not drink enough water, and if you are experiencing a headache then you may need to eat etc. These things happen because they are connected in one way or the other, when you body lacks a specific nutrient you need throughout your day, it can manifest in different ways, let’s take iron for example.
Iron is like the delivery truck for oxygen in your body. It helps your red blood cells carry oxygen from your lungs to all your tissues. The Red Cross Blood Donation explains that when you don't have enough iron, your body can't make enough of these oxygen-carrying cells. This is called iron deficiency, and it can lead to anemia. You might feel very tired, look pale, or get dizzy easily. Headaches, cold hands and feet, and weak hair and nails are also common signs. Because iron is so vital for many of your body's functions, a lack of it can really affect your overall health and energy levels. It's important to recognize these signs and get checked by a doctor if you suspect you might have an iron deficiency.
Sometimes, your body sends strange signals when it's missing something important. One unusual signal for iron deficiency is wanting to eat ice, which doctors call pagophagia. This is part of a bigger problem called pica, where people crave things that aren't food. Other examples of pica are wanting to eat dirt, clay, or even starch. It's not just these things; some people crave things like coal, chalk, paper, or hair. While kids get pica more often, adults with low iron can have it too, even if they don't have anaemia. This weird craving is your body's way of trying to tell you something's wrong, even if it seems odd.
Eating things that aren't food can be risky. For example, eating dirt could expose you to harmful germs or heavy metals. Eating large amounts of ice might not seem dangerous, but it can sometimes hurt your teeth or gums. Ingesting non-food items can lead to serious problems like poisoning, where harmful substances build up in your body. It can also cause blockages in your intestines, which can be very painful and dangerous. Symptoms like stomach pain, bloating, feeling very tired, nausea, and diarrhea can signal that something is wrong. If you find yourself constantly wanting to eat ice or other non-food items, it's really important to talk to a doctor. They can help figure out why you're having these cravings and make sure you stay safe.
If you're craving ice or other non-food items, it's important to see a doctor. They'll ask about your symptoms and might do some blood tests to check your iron levels. It's possible that your cravings are caused by iron deficiency, but they could also be related to other nutritional deficiencies or even emotional problems. Things like stress, obsessive-compulsive disorder, or developmental issues can sometimes cause pica. The doctor will try to figure out the root cause of your cravings. If it's an iron deficiency, they might suggest taking iron supplements or changing your diet. If it's an emotional issue, they might recommend talking to a therapist. Getting the right diagnosis and treatment is important for your health and well-being.
Credit: Canva
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.
Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.
Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).
The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.
"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.
Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?
The researchers analyzed more than 4,900 patients with IBD and discovered that:
Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.
The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.
Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s
The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.
The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.
The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.
The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.
As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.
Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.
Credit: Canva
With modern lifestyle changes, delayed childbearing, and other factors, infertility among Indians as young as 25 has become a looming public health concern for the country. However, the issue does not stop at the present.
A recent study published by The Menopause Society in their journal Menopause found that infertility may lead to earlier menopause, raising questions about the long-term reproductive health implications of this demographic shift.
Menopause is the final stage of a woman’s reproductive lifecycle, when menstruation stops, and she can no longer get pregnant. When the ovaries stop producing estrogen and progesterone, and a woman misses her period for 12 consecutive months, she has officially reached menopause.
Although menopause is a regular part of ageing, women typically reach menopause between 45 and 55 years of age. If menopause occurs before age 45, it is considered early menopause. If it occurs before 40, it is termed premature menopause – rarer than early menopause but involves the same causes, symptoms, and health risks.
While previous studies have been conducted to find a link between infertility and both early and premature menopause, they have had mixed results and did not consider the effect of different types of infertility; this study focuses on women with a history of primary infertility, women who have never achieved pregnancy, and have difficulty conceiving.
For the study, researchers examined the reproductive lifecycle of nearly 700 women in the U.S. – 461 with primary infertility and 530 without infertility – who were otherwise demographically similar (age, education, smoking status, etc.). It found that the 461 women had a 25% higher likelihood of reaching natural menopause about 1.2 years earlier than the 530.
Researchers also noted that women with underlying endometriosis as a cause of their infertility reached menopause between 40 and 44 years, much sooner than the national average of the United States, i.e., 52 years.
Possible explanations include accelerated ovarian ageing, reduced ovarian reserve, or the effects of endometriosis on ovarian function. But no matter the causes, the implications for women’s long-term health are substantial.
All women are born with a finite, predetermined number of eggs, which are sensitive to age, environmental toxins, medications, hormonal imbalances, and lifestyle factors. When exposed to such risk factors, especially over a long period of time, the DNA inside the eggs is altered, causing permanent genetic damage and reducing the egg quality and quantity.
As a core part of the reproductive process, any damage to the eggs directly affects reproductive health and, in turn, long-term systemic health.
Infertility impacts more than the ability to conceive and go through a pregnancy; it is often a sign of underlying health conditions and potential chronic illnesses, acting as a biomarker of increased all-cause mortality. Experiencing infertility itself increases a woman’s risk of developing cardiovascular disease, metabolic disorders, gynecologic cancers, etc., but reaching menopause early on top of that puts them at further health risk, adding osteoporosis and cognitive decline to the mix, along with the emotional distress and mental health challenges.
Indian women already reach menopause earlier than women in Western countries, with the average woman experiencing menopause at 46.2 years of age. With fertility rates dropping across the country, this study highlights just how critical it is to increase fertility awareness. Early screenings and regular fertility testing can help detect risks early and enable timely intervention, not only to combat the ongoing crisis but to ensure that women live healthy, fulfilling lives without impending morbidity.
Credit: AI Generated Image
A new oral GLP-1 medication has delivered encouraging results in a Phase 2b clinical trial for people living with type 2 diabetes.
According to AstraZeneca, its experimental tablet, elecoglipron, significantly lowered blood sugar levels and helped participants lose an average of 10.5% of their body weight after 26 weeks of treatment.
The findings were presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans and published in The Lancet on June 8.
Elecoglipron joins a growing wave of GLP-1 therapies being developed as pills, offering an alternative to injectable drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro.
The first oral GLP-1 treatment, Rybelsus from Novo Nordisk, received FDA approval in 2019 for adults with type 2 diabetes. Since then, oral options have continued to expand. In December 2025, the FDA approved a tablet version of Wegovy for weight management, while Eli Lilly’s oral obesity treatment, Foundayo, gained approval in April.
Independent experts say AstraZeneca’s results highlight the growing potential of non-injectable GLP-1 therapies for both diabetes and obesity treatment.
“It’s encouraging to see another oral medication demonstrating the benefits of GLP-1 therapy without requiring injections,” said Dr. Pouya Shafipour, a family and obesity medicine specialist at Providence Saint John’s Health Center in California.
Dr. Marilyn Tan, an endocrinologist and professor of medicine at Stanford University, noted that the rapidly expanding GLP-1 market could soon welcome another oral treatment option if elecoglipron succeeds in Phase 3 trials and ultimately secures FDA approval.
GLP-1 is a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called post-nutrition hormones, and they help you absorb the energy you just consumed.
GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. GLP-1 pills imitate that hormone, thereby silencing the food chatter in the brain. Interestingly, for some people, this food chatter is really quiet, and for others it is an outburst. So with GLP-1, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.
However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop them at 12 weeks; therefore, it is important for some but not for others.
The side effects of these pills include:
© 2024 Bennett, Coleman & Company Limited